Document Detail


Sustained virological response to pegylated interferon and ribavirin in patients with genotype 3 HCV cirrhosis.
MedLine Citation:
PMID:  20426280     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Chronic hepatitis C (CHC) virus infection in patients with cirrhosis is difficult to treat. There is limited data on the outcome of treatment for genotype 3 HCV infection with cirrhosis. AIMS: To determine sustained virological response (SVR) and its predictive factors in patients with cirrhosis due to genotype 3 HCV infection treated with pegylated interferon and ribavirin (RBV). METHODS: Consecutive patients with compensated cirrhosis due to HCV genotype 3 with positive HCV RNA treated with peg-IFN and RBV in our Gastroenterology Clinics during November 2005 to December 2006 were included in this study. Cirrhosis was diagnosed on the basis of liver biopsy and/or biochemical testing and ultrasound of abdomen. Primary end point of treatment was SVR. RESULTS: Of 66 patients, 32 (48.5%) were male. The mean age was 46.2 +/- 10.1 years; there were 61 (92.4%) patients with Child's A cirrhosis followed by 5 (7.6%) with Child's B type. 33 (50%) patients received pegylated interferon alfa-2a (180 microg/wk) with ribavirin and 33 (50%) received pegylated interferon alfa 2b (1 microg/kg/week) with ribavirin. EVR was achieved in 44 (66.7%), and ETR in 46 (69.7%); overall SVR was achieved in 38 (57.6%) patients. Factors predictive of SVR were age (p value = 0.03), treatment na?ve status (p value = 0.04) and EVR (p value < 0.001). Five patients were unable to complete the treatment due to side effects or cytopenias. CONCLUSIONS: Treatment of patients with HCV genotype 3, compensated cirrhosis, with pegylated interferon and ribavirin is effective and well tolerated.
Authors:
Amna Subhan Butt; Khalid Mumtaz; Irum Aqeel; Hasnain A Shah; Saeed Hamid; Wasim Jafri
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Tropical gastroenterology : official journal of the Digestive Diseases Foundation     Volume:  30     ISSN:  0250-636X     ISO Abbreviation:  Trop Gastroenterol     Publication Date:    2009 Oct-Dec
Date Detail:
Created Date:  2010-04-29     Completed Date:  2010-06-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8107122     Medline TA:  Trop Gastroenterol     Country:  India    
Other Details:
Languages:  eng     Pagination:  207-12     Citation Subset:  IM    
Affiliation:
Section of Gastroenterology, Department of Medicine, The Aga Khan University Hospital, Karachi, Pakistan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antiviral Agents / therapeutic use*
Female
Genotype
Hepatitis C, Chronic / drug therapy*,  genetics*
Humans
Interferon Alfa-2a / therapeutic use*
Liver Cirrhosis / drug therapy*,  genetics*,  virology*
Logistic Models
Male
Middle Aged
Polyethylene Glycols / therapeutic use*
Prospective Studies
Ribavirin / therapeutic use*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antiviral Agents; 0/Polyethylene Glycols; 0/peginterferon alfa-2a; 36791-04-5/Ribavirin; 76543-88-9/Interferon Alfa-2a
Comments/Corrections
Comment In:
Trop Gastroenterol. 2009 Oct-Dec;30(4):183-5   [PMID:  20426276 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of antioxidant therapy on hospital stay and complications in patients with early acute pancre...
Next Document:  Renal duplex Doppler ultrasound in patients with HCV related liver cirrhosis.